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A B S T R A C T
The European Space Agency (ESA) is currently expanding its efforts in identifying requirements and promoting
research towards optimizing radiation protection of astronauts. Space agencies use common limits for tissue
(deterministic) effects on the International Space Station. However, the agencies have in place different career
radiation exposure limits (for stochastic effects) for astronauts in low-Earth orbit missions. Moreover, no specific
limits for interplanetary missions are issued. Harmonization of risk models and dose limits for exploratory-class
missions are now operational priorities, in view of the short-term plans for international exploratory-class
human missions. The purpose of this paper is to report on the activity of the ESA Topical Team on space radiation
research, whose task was to identify the most pertinent research requirements for improved space radiation
protection and to develop a European space radiation risk model, to contribute to the efforts to reach interna-
tional consensus on dose limits for deep space. The Topical Team recommended ESA to promote the develop-
ment of a space radiation risk model based on European-specific expertise in: transport codes, radiobiological
modelling, risk assessment, and uncertainty analysis. The model should provide cancer and non-cancer radiation
risks for crews implementing exploratory missions. ESA should then support the International Commission on
Radiological Protection to harmonize international models and dose limits in deep space, and guarantee con-
tinuous support in Europe for accelerator-based research configured to improve the models and develop risk
mitigation strategies.
1. Introduction
Space radiation is generally recognized as a major health risk for
astronauts (Chancellor et al., 2014). With the impending Deep Space
Gateway and plans for moon and Mars exploration involving interna-
tional crews (ISECG, 2013), an international space radiological pro-
tection strategy has now a high priority.
For the International Space Station (ISS) that operates since 1998 in
Low Earth Orbit (LEO), all participating partner agencies (NASA for
USA, FSA for the Russian Federation, CSA for Canada, ESA for Europe
and JAXA for Japan) work on the basis of a common radiation pro-
tection framework mutually agreed upon for all ISS Crew
(Multilateral Medical Operations Panel, 2016). Each planned exposure
is executed in adherence to the As Low As Reasonably Achievable
(ALARA) principle of radiological protection (ICRP, 2007). Exposures to
ionizing radiation are managed by a combination of exposure limitation
and optimization practices that minimize risks. Despite the uniform
limits to prevent from tissue (deterministic) effects (Straube et al.,
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2010), not every agency did adopt and express limits for the entire
career (targeting stochastic effects) of its astronauts identically
(Table 1). In fact, ESA and CSA use a single career dose limit of 1 Sv for
all gender and ages, based on a recommendation from the International
Commission on Radiological Protection (ICRP) (ICRP, 1991). The
Russian Space Agency (RSA) use a specific model (Petrov, 2002; Petrov
et al., 1981; Shafirkin et al., 2002) that takes into account the whole
space environment, but the acceptable risk in the model also corre-
sponds to a career dose limit of 1 Sv in LEO. NASA (National Research
Council, 2012) and JAXA apply different limits based on their national
space radiation risk assessment models (McKenna-Lawlor et al., 2014).
For any mission, NASA calculates the acceptable number of safe days in
deep space as the maximum number of days resulting in a 3% risk of
exposure-induced death (REID) at the upper 95% confidence interval
(Cucinotta et al., 2013a). REID is limited to fatal cancers. NASA policy
only allows missions which do not lead to exceeding the number of safe
days in space. The requirement of a 95% confidence level depends on
the scientific data, and may be modified according to new results
coming from research. Cumulative exposures of ISS crewmembers to all
sources of ionizing radiation are limited as a consensus dose limit over
30 day and 1-year time intervals in order to prevent unacceptable de-
terministic effects to the blood-forming organs (BFO). The “blood-
forming organs” refers to bone marrow, spleen, and lymphatic tissues.
Active (red) bone marrow is a surrogate for BFO (Multilateral Medical
Operations Panel, 2016). No agency has issued any specific re-
commendation for limits in Beyond Low Earth Orbit (BLEO) missions
(McKenna-Lawlor, 2016; NCRP, 2006).
ESA is currently strengthening its initiatives in identifying require-
ments and promoting research towards optimizing radiation protection
for astronauts. ESA supports the development of common risk limits
and risk estimations or, in the absence of consensus, the development of
ESA methodologies for the purpose of human exploration of space. In
support of the above, ESA put in place a Topical Team (TT) to provide
expert advice on relevant research to be undertaken. This TT, supported
by the Radiation Protection Initiative (RPI) of the Directorate of Human
and Robotic Exploration, forms a forum for ESA and non-ESA experts
from space-science, biology, epidemiology, medicine and physics to
identify the most pertinent research requirements for improved space
radiation protection. As part of this initiative, the TT performed a de-
tailed survey on available “Ground-based facilities and models for space
radiation research” (Durante et al., 2017) which contribute to research
on risk assessment for exploration-class missions. Similarly, the RPI
conducted a multilateral summit (see Section 2) on Ionizing Radiation
and Human Health Risks in the frame of its medical and operational
charge. The purpose of this paper is to report in detail on future Eur-
opean research directions, required efforts and recommendation for
optimizing a space radiological protection that were identified by the
TT.
The research requirements identified by the TT broadly fall into
three main research areas, namely: improving characterizations of
ionizing radiation in space; increasing knowledge on the potential
detrimental health effects of space radiation exposure; and better
characterizing the associated risks to astronauts. The relatively short
term aim of providing an optimized approach to guide the occupational
radiation health risk assessment for astronauts, in terms of cancer and
non-cancer health effects, will enable improvements in effective risk
communication between space agency medical operations and astro-
nauts and aid decision-making relevant to human space missions. The
TT, therefore recommended ESA to promote the development of a
European Space Radiation Risk Model (ESRRM) based on innovations in
risk assessment and uncertainty analysis. Further longer-term im-
provements to the new ESRRM could be based on developments of
innovative radiation transport codes, refined RBE models and results
from nanodosimetry experiments. The ESRRM should be developed to
provide cancer and non-cancer radiation risks for crews in realistic
BLEO missions. A further important TT recommendation was for ESA to
support ICRP in future efforts to harmonize international models and
dose limits in BLEO in line with RPI and the International Systems
Maturation Team – Radiation (ISMT-RAD). The next section describes
the ESA initiatives in optimizing radiation protection of astronauts and
the subsequent three main sections describe in detail the research re-
quirements in each of these ESA identified main research areas.
2. The current initiatives of ESA in optimizing radiation
protection for astronauts
ESA's initiatives are partly carried out in collaboration with the
ISMT-RAD, which is a coordinated activity of ESA with other partner
national space agencies (NASA, RSA, JAXA, CSA) to provide radiation
protection for their crewmembers (Straube et al., 2010). The ISMT-RAD
experts have agreed to compare risk estimation methods of the different
agencies to reach a consensus on dose limits for multilateral human
space exploration. In December 2017, the ISMT-RAD convened at the
European Astronaut Centre in Cologne (Germany), to discuss the pos-
sibility of adopting an international consensus framework for human-
risk modelling and limits on astronaut exposures to ionizing radiation
for exploration-class space missions. Examples of such missions include
a cis-lunar (e.g., Deep Space Gateway), long-duration presence in a
“free-space”, habitat located outside the influence of the Earth's geo-
magnetic field, or a mission to a planetary surface such as Mars. The
outcome of this meeting was that ISMT-RAD group contacted the ICRP
explicitly to request direct recommendations and guidance from the
ICRP on the following critical topics identified at the meeting:
Non-cancer tissue effects of radiation. These include potential ra-
diation effects on the central nervous system (CNS) during spaceflight
(Jandial et al., 2018; Roberts et al., 2017), such as performance de-
crement or behavioral responses that may impact crew health and
mission success. A review (including the NASA CNS limits) of available
evidence and recommendations on additional research are required and
currently under way from the National Council of Radiological Pro-
tection (NCRP) (NCRP, 2016).
1. Inclusion of cardiovascular disease. Recent evidence points to a
substantial late radiation-induced risk, but the existence of a
threshold, although possible, is not proven (Hughson et al., 2017).
Recommendations for the inclusion of cardiovascular disease as a
detrimental health outcome are required.
2. Lens opacification (Chylack et al., 2012). Recommendations on the
occurrence and latency of lens opacification during a long duration
exploration-class mission that extends up to 3-years are required.
3. A common risk assessment framework and exposure limits.
Recommendations for establishing a common risk assessment fra-
mework and exposure limits for cancer risks for exploration-class
human spaceflight missions are required. Significant contributors to
uncertainty include radiation quality factors, low dose and dose rate
effects and transfer of risk from cell and animal studies and exposed
Table 1
Career effective dose limits (in Sv) for astronauts in LEO recommended by
different National Space Agency. Values for NASA and JAXA refer to a 1 year
mission, and are based on a 3% maximum REID caused by cancer within 95%
confidence limits. Values from McKenna-Lawlor et al. (2014).
Space agency Age at exposure (years)
Gender 30 40 50 60
NASA M 0.78 0.88 1.00 1.17
F 0.60 0.70 0.82 0.98
JAXA M 0.60 1.00 1.20 1.20
F 0.60 0.90 1.10 1.10
ESA M/F 1.00 1.00 1.00 1.00
RSA M/F 1.00 1.00 1.00 1.00
CSA M/F 1.00 1.00 1.00 1.00
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human populations such as the atomic bomb survivors (Cucinotta,
2015; Durante and Cucinotta, 2008).
4. Risk-model evaluation. An evaluation of results from a selection of
space agency-provided risk models for defined reference missions is
required (ISMT-RAD may also provide an independent evaluation).
The ISMT-RAD identified a substantial overlap between their needs
for safe space exploration and the following stated ICRP research
priorities:
• Effects of protracted exposures and low dose rates• Mechanisms of low-dose effects and dose-response models that take
account of them• Organ-specific, and age and gender differences in, sensitivity to
cancer induction• The role of genetic differences in determining individual sensitivity• Effects other than cancer and genetic effects and their contribution
to health detriment• Relating exposures, doses, and effects on population viability for
nonhuman biota• Reliability of dose assessments• Dosimetry and protection methods in medicine• Ethical and social dimensions of the system of radiological protec-
tion• Mechanisms for interaction with stakeholders
ESA supports the development of common ISMT-RAD risk limits and
risk estimations or, in the absence of international consensus, the de-
velopment of ESA methodologies for the purpose of human exploration
of space.
3. Improving characterizations of ionizing radiation in space
3.1. Measurements
There is a need for continued measurements of the energy, particle
and energy deposit spectra using spectrometers on satellites, the
International Space Station (ISS) and arctic high latitude balloons.
These inputs are needed to validate and update models. With a
benchmarked model it becomes possible to adequately calibrate the
dosimeters and use the data properly. Throughout cross calibrations
among different detectors (Berger et al., 2017; Narici et al., 2017a,b) is
needed to improve model validations. Furthermore, measuring the ra-
diation environment inside space habitats (i.e. the ISS (Narici et al.,
2017a,b; Zeitlin et al., 2019)) helps to improve understanding of the
variability of a radiation field due to complex and possibly rapidly
changing shielding, proper for the inside of a habitat. It has been en-
visaged that to properly fulfil these tasks, novel detectors, able to
provide detailed information on the radiation quality in increasingly
smaller packages, will be needed.
3.2. Environmental models
Galactic Cosmic ray (GCR) environmental models are developed to
provide a reliable input for radiation transport models. GCR models
currently in use are the Badhwar O'Neill 2014 (O'Neill et al., 2015),
DLR (Matthiä et al., 2013), and Nymmik (Nymmik et al., 1996) models.
These models are validated by measurements from balloon and satellite
measurements, such as measurements from ACE/CHRIS. Model un-
certainties are currently in the range of 20% and will be propagated
into effective dose calculation behind shielding. A further source of
uncertainty arises from the requirement to convert the effective doses
into the organ doses that are required for input into the health risk
assessment models. Therefore, continued measurements of the spectra
of the cosmic ray components are necessary to benchmark these models
and improve their reliability.
3.3. Transport codes
Any space radiation risk model, based on fundamental physics and
radiobiology, must start with the primary ionizing events in the human
cells. To estimate the biological damage caused by the ionizing events,
information about the ionization density along the particle tracks must
be known. Accurate estimations of the radicals, produced by primary
space radiation, must also be available. To achieve this information, we
first need to be able to calculate fluence, angular and energy deposition
distributions of both primary and secondary particles, including pro-
jectile and target fragments, neutrons, etc., produced when the primary
cosmic ray particles react with the spacecraft and the human body
(ICRP, 2013). To be able to estimate the radiation risks to humans in-
side complex geometries, nuclear reaction models and space radiation
transport codes are therefore needed (Sihver, 2008). In all particle and
heavy ion transport codes, the probability function that a projectile
particle will collide with a nucleus within a certain distance x in the
medium depends on the total reaction cross sections, which also scale
the calculated partial fragmentation cross sections (Norbury et al.,
2012). It is therefore crucial that accurate total reaction cross section
models are used in the transport calculations. Most transport codes use
different semi-empirical total reaction models which are not sufficiently
benchmarked for all systems of importance for space radiation due to a
lack of experimental data (Sihver et al., 2012).
A transport code which uses a simplified, numerically integral,
version of Boltzmann's transport equation, is called a deterministic
code. The Boltzmann equation calculates the mean number of particles
as a function of the phase-space coordinates. Different deterministic
computer codes are based on different approximations to the full
Boltzmann equation and/or on different models for the quantities
which are considered to be relevant for the transport calculation
(Durante and Cucinotta, 2011). Deterministic codes are fast since the
coefficients used in the Boltzmann equation represent very simple one-
particle quantities, and all correlations are neglected. Therefore, the
deterministic formulation does not elaborate a large amount of in-
formation as in the Monte Carlo (MC) based event generators described
below. One dimensional (1D) deterministic ray tracing models are very
fast, but do not consider out-off beam scattering or lateral leakage. The
calculated results can therefore be misleading. An example of a de-
terministic space radiation code is HZETRN (Wilson et al., 1997), used
by NASA. HZETRN employs numerical solutions to the time-in-
dependent, linear Boltzmann equation. It utilizes the continuous
slowing down approximation and a semi-inclusive/semi-empirical
abrasion-ablation model for the nuclear fragmentation cross sections.
HZETRN was originally 1D, but has been expanded to three dimensions
(3D) (Wilson et al., 2014). In Europe, the deterministic code TRiP98 is
used for heavy ion therapy in clinics (Krämer and Durante, 2010), and
would be the best candidate to become a European deterministic code
for fast dose estimation. Another approach is to calculate probability
density functions by using stochastic MC techniques (Truscott et al.,
2000), which would preserve information concerning correlations be-
tween different particles. However, with most of the MC codes one can
only obtain the mean value of one-body observables in phase space,
e.g., heat, flux, and dose.
In Table 2, some major 3D MC radiation transport codes are tabu-
lated. The first dynamic step of the nuclear reaction, leading to the
fragmentation cross sections of importance for space radiation, are most
often calculated with different versions of exclusive Intranuclear-Cas-
cade (INC) and Quantum Molecular Dynamics (QMD) models in MC
codes (Durante and Cucinotta, 2011). The QMD model can treat a nu-
clear reaction in a semi-classical many-body framework and describe all
correlations among the ejects. On the other hand, the INC models de-
scribe a nuclear reaction by sequential two-body collisions between
nucleons in a fixed target mean field. The second, statistical, de-ex-
citation step of the reaction, is calculated using different evaporation
models. In Europe, GEANT4 (Agostinelli et al., 2003), FLUKA
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(Battistoni, 2008), and PHITS (Sato et al., 2018) are the three major
multi-purpose three-dimensional Monte Carlo particle and heavy ion
transport codes. Since the heavier ions in the GCR will break up to form
lighter particles when penetrating the shielding of a spacecraft, and the
human body, the production cross sections for light target and pro-
jectile fragments are of great importance. However, when comparing
the simulated results from different transport codes, it has been shown
that there are still large uncertainties in their cross sections (Giraudo
et al., 2018; Matthiä et al., 2016). All models share a deficiency in the
knowledge of the fundamental light fragment and neutron production
cross sections that are critical to understanding the consequences of
GCR transmission through matter (shielding, spacecraft components,
and human tissue). There is in addition the need to identify the largest
uncertainties associated with calculating the transport of space radia-
tion through thick shielding as is the case in space mission applications.
To be able to correctly calculate the first physical and chemical steps
in the event chain leading to DNA and cell damage, in a space radiation
risk model, calculations of particle track structure and energy deposi-
tion distributions in 3D are needed (Bernal et al., 2013). This requires
3D MC simulations with conservation of energy and momentum event-
by-event, or analytical functions based on event-by-event calculations.
Monte Carlo codes provide a detailed treatment of the three-dimen-
sional transport of neutral particles and ions, simulating the continuous
distribution of energies and angles of scattered particles from available
double-differential scattering cross sections.
3.4. Track structure models
Determination of the cancer risk incurred from the exposure of
space radiation is an important requirement for the success of long-term
space missions. After the various components of space radiation have
been determined, they have to be properly weighted according to their
contribution to cancer induction relative to the induction rates from
low ionizing radiation. Currently, quality factors or relative biological
effectiveness factors (RBE) for cancer induction are used for the dif-
ferent radiation qualities (ICRP, 2007, 2003). Typically, these quality
factors are defined by national and international commissions based on
existing radiobiological data and presumed knowledge of the ionization
density distribution of the radiation field at a given point of interest.
The set of RBE values used in the NASA model (Cucinotta et al.,
2013a,b) is different from the values recommended by ICRP
(ICRP, 2007), and they are tumor-specific, owing to the experimental
observation that the RBE changes for different tumor types (Weil et al.,
2009). The RBE values are used in an amorphous track structure model
(Katz et al., 1996), where the radial dose for different heavy ions is
calculated and average values are used. Amorphous track structure
models are also used in Europe for heavy ion therapy (Grün et al.,
2012), where the primary endpoint is cell killing. Extension of the local
effect model (LEM) to other endpoints, such as cancer (Eley et al.,
2016), is possible and may result in a European approach to the RBE
calculation for space radiation.
3.5. Micro- and nano-dosimetry
Another option for evaluating and monitoring quality factors for
space radiation exposure is the use of very compact microdosimeters to
monitor space radiation quality. From the spectra recorded by the mi-
crodosimeters, the mean dose weighted lineal energy and average
quality factor can be determined using the protocol outlined in ICRU
report 36 (Booz et al., 1983). Microdosimetry records stochastic energy
deposition events in micrometer volumes and one assigns quality fac-
tors to components of the lineal energy spectrum. However, a quality
factor based on the frequency of critical DNA damage events at the nm-
scale would be more realistic. Therefore, nanodosimetry, which records
individual ionizations occurring in simulated DNA segments, can be
used to indirectly quantify DNA damage relevant to late effects. This
approach may be more directly related to cancer initiating events.
However, additional radiobiological research correlating nanodosi-
metry data with biological end-points such as mutations and cancer
induction will be needed to confirm this view. In fact, radiation seems
to play an important role in promoting carcinogenesis especially in
adults, and this inflammation-mediated mechanism is quite distinct
form that of DNA damage alone (Cucinotta and Durante, 2006; Shuryak
et al., 2010).
Several approaches have demonstrated the usefulness of nanodosi-
metry detectors (Grosswendt, 2005). However, the current technology
has its limitations, foremost its lack of portability due to the need of
sophisticated pumping and gas systems and its slow data acquisition
time when sampling from a single sensitive volume. If the realm of
nanodosimetry is to be investigated further, in particular for applica-
tions in space radiation protection and monitoring, an improved na-
nodosimeter is required that can be deployed on spacecraft. For this,
the basic concept of the configuration of current nanodosimetry appa-
ratus may need to be revisited (Schulte et al., 2008).
The approach of nanodosimetry based quality factors has also other
limitations. For example, it is not clear which nanodosimetric quantities
shall be used to quantify DNA double strand breaks (DSBs). Current
nanodosimeters do not give any information on the regional association
of complex DSBs. It could be that a realistic quality factor can be only
obtained by a combination of a nanodosimetric quantity with a model
describing chromosomal radiation interaction (Schneider et al., 2018).
In summary, nanodosimetric data yield meaningful quality factors
for space radiation protection, which are based on a biological end-
point, namely the number of complex DSBs. The advantage of nano-
dosimetry is that it does not require the identification of individual
particles in a complex radiation field at the same time as it provides
information about the ionization density on a DNA scale along the
particle tracks. The practical application of nanodosimetry in space
Table 2
Examples of some of the major MC particle transport codes.
Name Developer Application Language Features
MCNP
(X,5,6)
LANL Nuc. Energy, Nuc. Physics FORTRAN World standard of nuclear energy
High reliability, Criticality
GEANT4 CERN etc. High En. Physics, Radiology,
Astronomy
C++ Object-oriented, Platform to integrate models and tools developed all over the world, applied
in magnetic and mass shielding calculations (see eg. Planetocosmos), space science
FLUKA CERN, INFN High En. Physics, Accelerator,
Radiology, Astronomy
FORTRAN Applied to accelerator shielding design, radio therapy, space science
EGS KEK, SLAC Radiology FORTRAN EM cascade code
Applied to mainly radiology
SuperMC FDS Fusion, Radiology C++ Developed for ITER
High CAD-affinity, Visualization
PHITS JAEA, RIST,
KEK
Accelerator, Radiology, Astronomy FORTRAN Easy start-up
Applied to accelerator design, radiology, space science
SHIELD-HIT INR Accelerator, Radiology, Astronomy FORTRAN Applied to accelerator design, radiology, space science
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radiation protection requires further technical development, in parti-
cular, of compact nanodosimeters and of biological verification studies
(Schulte et al., 2008).
4. Increasing direct knowledge about the potential detrimental
health effects of space radiation exposure
4.1. Missing biology for risk assessment
It has been pointed out many times that the main contributor to
uncertainty in space radiation risk comes from the biological effects of
cosmic radiation (Durante and Cucinotta, 2008). Due to the low dose
rate and the technical complications in performing radiation experi-
ments in LEO, most of our knowledge is derived from ground-based
accelerator experiments (Durante and Kronenberg, 2005). NASA has
recognized long ago the necessity of funding research in this direction,
and this commitment led to the construction of the NASA Space Ra-
diation Laboratory (NSRL) (La Tessa et al., 2016) at the Brookhaven
National Laboratory in Upton (NY) and to fund independent US re-
search groups to perform space-relevant radiobiological research at
NSRL (Schimmerling, 2016, 2003).
ESA has followed the same direction, first funding a preliminary
study on Investigation of Biological Effects of radiation (IBER) in 2008
(Durante et al., 2007) and then implementing a research program at the
SIS18 accelerator of the GSI Helmholtz Center in Darmstadt
(Durante et al., 2010). ESA also supported a TT on space radiation to
provide recommendations on space radiation research. Recently the TT
has re-evaluated the IBER report (Durante et al., 2017), also con-
sidering the EU THESEUS roadmap (THESEUS, 2014) published in
2014 and the 2016 ESA roadmap (ESA, 2016) for future research. The
TT review encompassed the previous IBER activity with the ESA and
THESEUS roadmap, as well as with the NASA Human Research
Roadmap (NASA, 2015) and the MELODI (EU Multidisciplinary Low
Dose Initiative, 2018; Kreuzer et al., 2017) low-dose initiative in Europe
to identify the main issues that would most benefit European team
expertise and funded projects. In Table 3 the IBER research priorities
are shown in correspondence with NASA's roadmap gaps. While the US
will support the Space Radiation Health Program at NSRL, ESA will
continue supporting IBER at GSI and the five European heavy-ion in-
frastructures via a continuously-open research announcement (CORA)
for ground-based facilities (GBF). The new facility FAIR (Durante et al.,
2019), currently under construction in Darmstadt, will start operations
in 2025 with a strong program in applied nuclear sciences (Durante
et al., 2019a,b). According to an ESA study led by the Fraunhofer In-
stitute (Metzger et al., 2016), FAIR will become the leading GCR si-
mulator worldwide because of the very high energy (around 10 GeV/n)
achievable for heavy ions. ESA has signed in March 2018 a Memor-
andum of Understanding with FAIR for future applications of FAIR in
space radiation research.
4.2. Considerations required for developing an international occupational
cohort study
Long-term health risk assessment (HRA) approaches include
building an international occupational cohort study of astronauts. This
would involve preparing the European epidemiological data in a form
that is suitable for eventually combining into such a study. There are
already many radiation-epidemiological studies available from occu-
pational groups e.g., airline pilots (Hammer et al., 2012) and uranium
miners (Walsh et al., 2015), that have provided very useful quantifi-
cations of the occupational radiation risks arising from many detri-
mental health effects such as cancer. Cohort studies (Grimes and
Schulz, 2002) are usually considered to be the gold-standard amongst
the various types of studies possible. Some statistics pertinent to the
potential development of an international astronaut cohort are as fol-
lows (data from www.worldspaceflight.com). World-wide,
approximately 560 astronauts have flown to date. The total time in
space has been currently estimated at 141 person-years. Assuming an
average age at exposure of 40 years and epidemiological follow-up to
age 80 years, the estimated person-years at risk for the currently ex-
posed astronauts would be 22,400 (i.e., 560 (80–40)). The major con-
tributors of data to such an international cohort study would be the
USA, Russia and Europe with 348, 116 and 46 flown astronauts re-
spectively. A potential first-step in international cohort development
would be for the non-USA space agencies, including ESA, to already
start to ensure that their archives for health effects and exposure history
data (for flown, ground and in-training astronauts) are stored in a way
that is compatible with the largest NASA databank.
The IBER research program aims at filling the gaps in knowledge
concerning the effects of space radiation on astronauts. A major issue is
the effectiveness of GCR at low doses for causing carcinogenesis and
late tissue degenerative effects (especially to the CNS and the cardio-
vascular system). Another point is the current lack of information on
the dependency for acute effects of particle charge and energy and dose
rate. Do low dose effects follow the same biological pathways known to
be involved in disease progression for high doses? Knowledge of the
health risks associated with exposures to ionizing radiation above
100mGy is quite well established, while lower dose risks are inferred
from higher level exposure information (ICRP, 2007). Uncertainties
regarding these health risks need to be clarified with the help of me-
chanistic studies. The EU-funded network of excellence DOREMI
(2010–2016) has shown that low dose and low dose-rate effects are the
result of complex network responses including: genetic, epigenetic,
metabolic and immunological regulation. Evidence is available for the
existence of nonlinear biological responses in the low and medium dose
range as well as effects other than that of classical DNA damage
(Averbeck et al., 2018). It should be also noted that there is a lack of
information concerning longer-term outcomes in the area of adverse
behavioral health (NCRP, 2016) and cardiovascular events
(Hughson et al., 2017). Interaction across risk domains is the biggest
challenge at all.
5. Potential improvements in the health risk assessment for
astronauts
This section first gives details of the main considerations required
for developing a European risk model in terms of which time integrated
risk measures may be suitable. Then the main uncertainties that need to
be considered in the development of a European risk model are illu-
strated, based on calculations carried out for one particular choice of
time integrated risk measure.
5.1. Main considerations underlying the development of a European risk
model
Short-term approaches include the development of an ESRRM for
predicting the radiation related risk of detrimental health effects.
Development of an ESRRM requires: the adoption of suitable time in-
tegrated risk measures (e.g., Lifetime Attributable Risk (LAR)) which
are based on risk results from radiation epidemiology cohorts (e.g.,
Excess Relative or Absolute Risk (ERR or EAR); pertinent assumptions
(e.g., for smoking and medical-screening status, dose and dose rate
effectiveness (DDREF), the shape of the risk to dose response (e.g.,
linear-no-threshold (LNT)), the neutron relative biological effectiveness
(RBE); and input data (e.g., for population based age specific mortality
& cancer rates). All potentially suitable currently available risk assess-
ment measures build on ERR or EAR risks per unit radiation dose (e.g.,
from the Life Span Study of survivors of the WWII atomic bombings in
Hiroshima and Nagasaki (Grant et al., 2017)).
One measure of risk obtained retrospectively, directly from ERR and
EAR, once a cancer has occurred, is the probability of causation (PoC) –
as recently implemented for industrial compensation claims in
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Germany (ProZES: www.bfs.de). Other measures often used in radiation
epidemiology for predictive risk assessment, include Lifetime
Attributable Risk (LAR), Risk of Exposure Induced Death (REID) and
Excess Lifetime Risk (ELR) (Kellerer et al., 2001) but all have some
distinct disadvantages for astronaut HRA. One such disadvantage is that
conventionally applied time-integrated risks are based on current po-
pulation and health statistical data that are not well suited for risk es-
timates for Astronauts who are not readily represented by the general
population due to distinctly different levels of life-style factors such as
smoking and fitness and different levels of post-mission cancer
screening. A second disadvantage is that conventionally applied risks
are not optimal for risk projections decades into the future due to large
uncertainties in developments of future secular trends in the popula-
tion-specific disease rates. Novel approaches may be more suitable for
application to astronauts, such as a risk representation with the Ra-
diation Attributed Decrease in Survival (RADS) which is only based on
the radiation-attributed hazard, is insensitive to competing risks and
eminently suitable for risk projections for highly atypical groups of
exposed persons, such as astronauts (Ulanowski et al., 2019). RADS
represents a cumulative radiation risk conditional on survival until a
certain age and is known in general statistical literature as “cumulative
risk”.
Decisions to be made in connection with developing a European risk
model for astronaut HRA include: should the outcome of detrimental
health effects (incidence or mortality) be considered?; which outcomes
should be considered (e.g., the most radiation sensitive cancer sites
comprising the thyroid, female breast; leukemia, plus all other solid
cancers, as in the Fukushima HRA (Walsh et al., 2014))?; which risk
measures should be applied (ERR, EAR, PoC, LAR, REID or a novel
approach such as RADS)?; and which uncertainties should be con-
sidered? (see the next section). With a series of well justified choices, it
should be possible to build a European risk model that accounts for the
major uncertainties, the atypical nature of astronauts and is optimally
applicable at the potentially high doses that may be relevant beyond
low earth orbit.
5.2. The main uncertainties that need to be considered in the development of
a European risk model
Analyses of the epidemiological data on the Japanese A-bomb sur-
vivors (Grant et al., 2017), who were exposed to γ-rays and neutrons,
provide detailed information on the dose-response of radiation-induced
cancer and form the main basis for current space radiation risk models.
Since the dose range of main interest for radiation protection purposes
is of the order of a few tens to a few hundred mGy, the analysis of the A-
bomb survivors often focuses on this range. However, estimates of
cancer risk for larger doses are becoming more important for long-term
human space missions. Therefore, future space solid cancer and
leukemia mortality/incidence radiation risk models should apply risk
estimates valid at doses that include one Gy and above. It is possible to
extend current analyses of the A-bomb survivors’ data to include some
high-dose categories.
Usually colon dose, as supplied with publicly available A-bomb
survivor datasets, is used to obtain risk factors for all solid cancers.
However, it is known that the use of colon dose underestimates the
average dose to all organs (Walsh et al., 2004). Thus, a newly developed
space radiation risk model should include organ-averaged weighted
doses instead of the colon weighted dose.
A neutron RBE of 10 is traditionally applied in the analyses of the A-
bomb survivor data. However, there are some reported indications of a
high neutron dose contribution (Kellerer et al., 2006). Therefore, the
impact of neutron RBE on space radiation protection should be ana-
lyzed by using three different values for the relative biological effec-
tiveness of neutrons (10, 35 and 100). In addition, the impact of a dose
dependent RBE for neutrons determined by Sasaki et al. (2006) should
be investigated.
Further improvement of the risk model can be achieved by fitting
the data using a linear and a linear-exponential dose-response re-
lationship using a variation in the dose and dose-rate effectiveness
factor (DDREF). Combined analyses of the A-bomb survivor data with
data from radiotherapy patient cohorts (Newhauser and Durante, 2011;
Schneider and Walsh, 2008) can also be used to further improve risk
models, in particular the risk dependence on age at exposure and at-
tained age (Schneider and Walsh, 2015).
First estimates imply that the use of organ-averaged dose instead of
colon dose would reduce risk by around 30%. A dose-dependent neu-
tron RBE could lower risk by about 15–20% (Schneider and
Walsh, 2009). The bending-over of the dose-response relationship for
radiation induced cancer could result in a reduction of radiation risk by
around 5% for dose levels typical for human space missions. In Fig. 1
the impact of these first estimates is shown by a comparison to the
results of the NASA risk model (Cucinotta et al., 2013a) in terms of risk
of exposure induced cancer death (REID). The comparison was done for
solar minimum and 5 g/cm2 aluminum shielding for a variable RBE, a
linear-exponential model and an astronaut age of 40 years at exposure
to 0.084 Sv for a long lunar mission, or approximately 1 Sv for a Mars
mission (see Fig. 1 for details). Clearly it is seen that a re-evaluation of
the risk factors could impact radiation risk estimates for space crews on
long-term mission above 500 days potentially exposed to doses up to 1
Sv or even higher.
6. Conclusions
Long-term, crewed international space missions will become a rea-
lity in the 21st century (ISECG, 2013). Space radiation risk is generally
considered as the main potential showstopper for safe exploration of the
Fig. 1. REID in% for solid cancer mortality for solar minimum and 5 g/cm2 aluminum shielding for variable RBE, a linear-exponential model and age at exposure 40
years. The figure shows a comparison between the NASA calculations and first estimates of potential new risk factors.
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Solar system (Chancellor et al., 2014), but until now the space agencies
use different models to calculate the maximum permissible radiation
dose for the crew, thereby resulting in different dose limits (McKenna-
Lawlor et al., 2014). For BLEO there are no risk limits defined, but
models can be applied (Cucinotta et al., 2017). Ethical considerations
support the concept that the dose limits should be based on acceptable
risk for astronauts. Attempts to dismiss all the limits and resort to e.g.
informed consent have been criticized according to the ALARA prin-
ciple (Kahn et al., 2014; Shuchman, 2014). Because the dose for a
mission to Mars is estimated to amount to roughly 1 Sv (Zeitlin et al.,
2013), and is therefore close to the dose limit for all agencies, at the
moment there is a paradoxical situation that an international explora-
tion mission would be essentially impossible, since some astronauts
would be forced to leave the mission before others depending on the
dose limit set by their space agency. The TT recommended ESA to
promote the development of a new ESRRM based on innovation and
European-specific expertise in transport codes, radiobiological model-
ling, risk assessment and uncertainty analysis. Finally, the ESRRM could
also be used in the European Radiation Facilities Network (ERFNet, ESA
project at feasibility stage), an infrastructures network managed by a
smart system that aims at optimizing space habitat designs to mitigate
radiation risk.
A further important TT recommendation was for ESA to support
ICRP in future efforts to harmonize international models and dose limits
for BLEO among the different agencies. Finally, the TT recommended to
continue to increase the investment in radiobiology and physics re-
search at accelerators in Europe (IBER).
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